Filing summary
Filing identity: The supplied filing is Nanophase Technologies Corporation’s Form 10-K for the fiscal year ended December 31, 2012, filed March 29, 2013. This does not match the request metadata naming SOLESENCE, INC. The filing reports annual results; it does not provide clear standalone fourth-quarter financial results.
Business context and reporting period
Nanophase develops and manufactures engineered nano- and sub-micron materials used in personal care and sunscreen products, coatings, polishing, plastics, and other applications. It sells through a major market partner and directly to customers, and describes its commercial opportunity as dependent on customer testing and adoption cycles that can span one to five years.
Financial performance and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Total revenue | $10.04 million | $9.65 million |
| Product revenue | $9.73 million | $9.32 million |
| Gross profit | $2.64 million | $2.33 million |
| Gross margin | 26.3% | 24.1% |
| Operating loss | $2.39 million | $3.36 million |
| Net loss | $2.39 million | $3.36 million |
| Net loss per share | $0.10 | $0.16 |
| Cash used in operating activities | $0.60 million | $2.92 million |
Cash and cash equivalents were $4.12 million and short-term investments were $30,000 at year-end 2012, versus $2.69 million and $30,000, respectively, a year earlier. Current assets were $6.59 million and current liabilities $1.20 million. The company reported no conventional debt, but had approximately $97,000 of capital lease obligations. Net cash provided by financing activities was $2.20 million, principally from a fully subscribed rights offering; 7.25 million shares were issued at $0.33 each, generating approximately $2.22 million net.
Changes versus 2011
- Revenue grew 4.0%; product revenue rose, with growth from the largest customer and newer direct customers partly offset by lower sales to the second-largest customer.
- Gross margin improved to 26.3% from 24.1%, while cost of revenue increased modestly. Management attributed the margin improvement in part to production efficiencies and said higher volumes could improve fixed-cost absorption.
- Operating and net losses narrowed by about $1.0 million. Research and development expense declined to $1.63 million from $1.74 million; selling, general and administrative expense declined to $3.40 million from $3.95 million.
- Operating cash use fell to $0.60 million from $2.92 million. The filing attributes much of the prior-year cash use to working-capital changes and notes lower cerium oxide costs and sales of previously purchased material in 2012.
- Revenue concentration shifted: the top three customers represented 67%, 9%, and 5% of 2012 revenue, compared with 54%, 21%, and 7% in 2011.
Outlook, risks, and unusual items
- Management expected growth in customer adoption in 2013 and beyond, while acknowledging that opportunities were at different stages of testing and qualification. It expected an annual loss in 2013 and said available cash, operating cash flows, and accessible capital should fund plans through 2013.
- Planned 2013 capital spending for currently known needs was estimated at $300,000–$500,000. Management said research and development expense was not expected to increase significantly.
- Customer concentration is a major risk: BASF accounted for approximately 67% of 2012 revenue. BASF supply agreements can, under specified financial or contractual triggers, give BASF rights to license technology and acquire certain production equipment. The minimum-cash threshold in the relevant covenant was reduced to $1 million during 2012; year-end cash and investments were approximately $4.15 million.
- The CIK Nanotek license agreement expires March 31, 2013. Related royalties were $279,000 in 2012; the planned subsequent arrangement is non-exclusive and royalty-free, so management expected other revenue to be substantially lower.
- Cerium oxide supply and pricing improved during 2012 but remained a risk to polishing-market customer acceptance. Other risks include prolonged adoption cycles, volatile raw-material costs, competition, limited access to capital, and reliance on key customers and partners.
- The company voluntarily moved its stock from Nasdaq to OTCQB in March 2012 after a period of noncompliance with Nasdaq’s minimum bid-price requirement. The move may affect access to financial markets.
- The filing reports no legal proceedings. The independent auditor gave an unqualified opinion on the financial statements; management assessed disclosure controls and internal control over financial reporting as effective, with no auditor attestation of internal controls included.
Most important facts for investors to verify
- Confirm the issuer identity: this filing is for Nanophase Technologies Corporation, not the company named in the request metadata.
- Track BASF sales concentration, new customer conversions, and any change in BASF contractual rights or covenant status.
- Compare 2013 actual losses, operating cash flow, and capital spending with management’s stated expectations and year-end liquidity.
- Verify the post-March 2013 CIK Nanotek arrangement and the resulting effect on royalty and total revenue.
- Monitor cerium oxide availability and cost, polishing customer demand, and whether improved gross margins persist as product mix and volume change.
- Assess the impact of the 2012 rights offering on share count and the company’s ability to obtain future financing.